Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma (HCC), according to data presented at the International Liver Congress 2011.1

A new study found thalidomide gave HCC patients who'd undergone grossly curative resection surgical removal of the cancerous part of the liver double the two-year disease free survival rate (65%) compared to placebo (33%).

However, the study did find that the two-year overall survival rate was comparable between patients treated with thalidomide and patients given placebo – 84.2% and 85.7% respectively.

Daniele Prati, EASL's Scientific Committee Member and Press Committee Chairman, commented: "Current options for adjuvant therapy in HCC are very limited and clinical trial results have been disappointing. Thalidomide has already been proven to work well in a number of other areas and this study shows it could potentially benefit HCC patients who are particularly difficult to treat. Overall, it is important to continue research in evaluating adjuvant therapy in HCC."

Surgery is the main form of treatment for HCC, but is only possible for a small proportion of those afflicted. Even after curative resection, recurrence is common and is the main cause of death. Adjuvant therapy that is, chemotherapy after surgery – is thus attempted to try to improve outcomes.2

The study is promising because there is currently no adjuvant therapy for HCC patients following curative resection.

Indeed, the most up-to-date Cochrane Review of adjuvant therapies for HCC (conducted prior to this thalidomide study) found insufficient evidence to show that previously investigated adjuvant therapies increased survival for HCC, and only limited evidence to suggest that adjuvant therapy was useful in disease-free survival.2

In the double-blind, placebo controlled, randomized, comparative phase-II study, 42 patients were given 200mg per day oral dose of thalidomide (Arm A, 21 patients) or 200mg per day oral dose of placebo (Arm B, 21 patients). Patients started treatment within 6 weeks of complete tumor resection and carried on treatment for 12 months, or until they encountered disease recurrence, intolerably toxicity, or withdrew consent. Overall, thalidomide showed a good tolerability profile.

is currently approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) in the US for the treatment of multiple myeloma (a cancer of the bone marrow).3,4


Explore further

Genetic signatures provide new direction in liver cancer

More information: References

1. Ho M-C et al. A randomized pilot phase II study of thalidomide as adjuvant therapy in patient with high recurrence risk hepatocellular carcinoma. Abstract presented at The International Liver Congress 2011. www1.easl.eu/easl2011/program/Orals/342.htm

2. Samuel M et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD001199. DOI: 10.1002/14651858.CD001199.pub2.

3. European Medicines Agency. www.ema.europa.eu/ema/index.js … 1d124&jsenabled=true. Accessed 09.03.2011.

4. EU-orphan. www.euorphan.com:81/active_sub … enu=3&alfa=T&alfa1=U . Accessed 09.03.2011

Provided by European Association for the Study of the Liver
Citation: Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients (2011, April 2) retrieved 26 January 2021 from https://medicalxpress.com/news/2011-04-thalidomide-efficacy-adjuvant-therapy-hepatocellular.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments